Amundi Portfolio holdings
Amundi, established in 2010 through the merger of Crédit Agricole and Société Générale’s asset management arms, is Europe’s largest asset management firm, headquartered in Paris, France, overseeing €2.2 trillion ($2.3 trillion USD) in assets as of late 2024. Serving institutional clients, financial advisors, and retail investors across 35 countries, Amundi offers a broad spectrum of investment solutions, including active and passive funds, ETFs, and sustainable investing options, with a strong focus on cost efficiency and ESG (environmental, social, governance) principles. The firm’s growth has been fueled by strategic acquisitions, such as Pioneer Investments in 2017 and Lyxor in 2021, enhancing its global reach and expertise in index tracking and alternatives. Majority-owned by Crédit Agricole, Amundi combines French financial heritage with a modern, client-centric approach, maintaining a dominant position in Europe while expanding in Asia and the Americas.
Top Buys
| 1 |
Apple
AAPL
|
+$2.98B |
| 2 |
NVIDIA
NVDA
|
+$1.91B |
| 3 |
Broadcom
AVGO
|
+$1.82B |
| 4 |
Microsoft
MSFT
|
+$1.51B |
| 5 |
Amazon
AMZN
|
+$1.3B |
Top Sells
| 1 |
Qualcomm
QCOM
|
+$876M |
| 2 |
UnitedHealth
UNH
|
+$780M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$647M |
| 4 |
Marsh & McLennan
MMC
|
+$621M |
| 5 |
PepsiCo
PEP
|
+$445M |
Sector Composition
| 1 | Technology | 31.18% |
| 2 | Financials | 12.47% |
| 3 | Consumer Discretionary | 11.86% |
| 4 | Healthcare | 11.61% |
| 5 | Communication Services | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1926
iShares Core S&P Mid-Cap ETF
IJH
$100B
| $1.11K | ﹤0.01% |
20
| – | – |
|
|
HPP
1927
Hudson Pacific Properties
HPP
$1.15B
| $1.11K | ﹤0.01% |
419
+296
| +241% | +$784 |
|
1928
Primoris Services
PRIM
$6.26B
| $1.11K | ﹤0.01% |
20
+11
| +122% | +$608 |
|
1929
Excelerate Energy
EE
$736M
| $1.09K | ﹤0.01% |
42
+20
| +91% | +$518 |
|
1930
Warby Parker
WRBY
$3.26B
| $1.08K | ﹤0.01% |
67
+33
| +97% | +$532 |
|
1931
Arcutis Biotherapeutics
ARQT
$2.15B
| $1.07K | ﹤0.01% |
+66
| New | +$1.07K |
|
1932
Douglas Dynamics
PLOW
$767M
| $1.06K | ﹤0.01% |
46
| – | – |
|
1933
Amalgamated Financial
AMAL
$871M
| $1.06K | ﹤0.01% |
39
+20
| +105% | +$543 |
|
1934
Viridian Therapeutics
VRDN
$1.62B
| $1.05K | ﹤0.01% |
83
+5
| +6% | +$63 |
|
|
MAGN
1935
Magnera Corporation
MAGN
$420M
| $1.04K | ﹤0.01% |
61
+14
| +30% | +$239 |
|
1936
Casella Waste Systems
CWST
$5.92B
| $1.04K | ﹤0.01% |
+9
| New | +$1.04K |
|
1937
Fabrinet
FN
$13.2B
| $1.04K | ﹤0.01% |
6
+4
| +200% | +$690 |
|
1938
Huron Consulting
HURN
$2.41B
| $1.03K | ﹤0.01% |
+7
| New | +$1.03K |
|
1939
Cross Country Healthcare
CCRN
$460M
| $1.02K | ﹤0.01% |
69
-26,425
| -100% | -$392K |
|
1940
Powell Industries
POWL
$3.29B
| $1.02K | ﹤0.01% |
6
-4,358
| -100% | -$740K |
|
1941
Lumentum
LITE
$10.4B
| $1.02K | ﹤0.01% |
19
-111,401
| -100% | -$5.96M |
|
1942
Vera Therapeutics
VERA
$1.6B
| $1K | ﹤0.01% |
44
+28
| +175% | +$637 |
|
1943
Crawford & Co Class A
CRD.A
$543M
| $978 | ﹤0.01% |
92
+17
| +23% | +$181 |
|
1944
Kenon Holdings
KEN
$2.37B
| $975 | ﹤0.01% |
30
+19
| +173% | +$618 |
|
1945
NeoGenomics
NEO
$1.02B
| $959 | ﹤0.01% |
110
+63
| +134% | +$549 |
|
1946
Savara
SVRA
$665M
| $954 | ﹤0.01% |
329
+27
| +9% | +$78 |
|
1947
RBC Bearings
RBC
$12.1B
| $952 | ﹤0.01% |
+3
| New | +$952 |
|
1948
Kymera Therapeutics
KYMR
$3.11B
| $948 | ﹤0.01% |
40
+21
| +111% | +$498 |
|
1949
Federated Hermes
FHI
$4.07B
| $947 | ﹤0.01% |
+24
| New | +$947 |
|
1950
Graham Holdings Company
GHC
$4.97B
| $945 | ﹤0.01% |
+1
| New | +$945 |
|